The capital will support ongoing clinical trials in multiple locations and advance development for Lung Therapeutics’ “transformative” drug for fibrosis, LTI-03.
The company has now raised $17 million in outside funding, aside from the $27 million awarded for discovery research and development.
The latest raise was headed by Bios Partners, a life sciences private equity firm out of Dallas and Fort Worth, Texas.
More articles on supply chain:
Mylan keeps EpiPen costs high despite intense public scrutiny
6 FDA decisions to keep an eye on in June
C-suites containing supply chain leaders have better operational performance: 7 survey insights
